Sign in →

Test Code IGFPN Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3 Growth Panel, Serum


Necessary Information


Necessary Information

Indicate patient's age and sex.



Specimen Required


Patient Preparation: For 12 hours before specimen collection, patient should not take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: 2 Plastic vials

Specimen Volume: 1.6 mL Serum

Collection Instructions: Centrifuge and aliquot serum into 2 plastic vials, each containing 0.8 mL of serum.


Useful For

Evaluation of growth disorders

 

Evaluation of growth hormone deficiency or excess in children and adults

 

Monitoring of recombinant human growth hormone treatment

 

Follow-up of individuals with acromegaly and gigantism

Profile Information

Test ID Reporting Name Available Separately Always Performed
IGF1S Insulin-Like Growth Factor 1, S Yes Yes
IGFB3 IGFBP-3, S Yes Yes

Method Name

IGF1S: Chemiluminescence

IGFB3: Enzyme-Labeled Chemiluminescent Immunometric Assay

Reporting Name

IGF-1, IGFBP-3 Growth Panel

Specimen Type

Serum

Specimen Minimum Volume

Serum: 0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Frozen (preferred) 14 days
  Ambient  72 hours
  Refrigerated  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus Reject

Reference Values

INSULIN-LIKE GROWTH FACTOR 1

Male:

<1 year: 27.0-157.0 ng/mL

1 year: 29.7-166.8 ng/mL

2 years: 33.9-183.9 ng/mL

3 years: 39.0-204.5 ng/mL

4 years: 44.3-225.0 ng/mL

5 years: 50.0-245.5 ng/mL

6 years: 56.2-267.1 ng/mL

7 years: 63.4-291.9  ng/mL

8 years: 72.4-323.1 ng/mL

9 years: 83.6-361.6 ng/mL

10 years: 96.9-406.6 ng/mL

11 years: 111.6-454.4 ng/mL

12 years: 126.1-498.7 ng/mL

13 years: 138.6-532.5 ng/mL

14 years: 147.5-551.2 ng/mL

15 years: 152.2-553.5 ng/mL

16 years: 152.9-541.8 ng/mL

17 years: 150.6-520.6 ng/mL

18 years: 146.2-493.6 ng/mL

19 years: 140.2-462.7 ng/mL

20 years: 133.1-430.0 ng/mL

21-25 years: 115.2-354.8 ng/mL

26-30 years: 97.9-281.6 ng/mL

31-35 years: 88.3- 246.0 ng/mL

36-40 years: 83.4-232.7 ng/mL

41-45 years: 74.9-216.4 ng/mL

46-50 years: 66.9-205.1 ng/mL

51-55 years: 60.6-200.3 ng/mL

56-60 years: 54.3-194.2 ng/mL

61-65 years: 48.8-187.7 ng/mL

66-70 years: 46.5-191.9 ng/mL

71-75 years: 40.9-179.2 ng/mL

76-80 years: 37.1-172.0 ng/mL

81-85 years: 33.8-165.4 ng/mL

86-90 years: 32.2-166.1 ng/mL

 

Females:

<1 year: 17.9-125.6 ng/mL

1 year: 19.5-132.3 ng/mL

2 years: 22.2-145.4 ng/mL

3 years: 25.9-164.2 ng/mL

4 years: 30.7-187.8 ng/mL

5 years: 36.2-214.4 ng/mL

6 years: 42.0-240.4 ng/mL

7 years: 48.6-269.6 ng/mL

8 years: 56.9-305.3 ng/mL

9 years: 67.2-349.4 ng/mL

10 years: 79.5-400.3 ng/mL

11 years: 92.6-452.6 ng/mL

12 years: 105.3- 499.1 ng/mL

13 years: 115.9-533.4 ng/mL

14 years: 123.4-552.0 ng/mL

15 years: 127.4-554.2 ng/mL

16 years: 127.9-541.5 ng/mL

17 years: 125.3-517.3 ng/mL

18 years: 120.5-485.8 ng/mL

19 years: 114.4-450.8 ng/mL

20 years: 107.8-416.0 ng/mL

21-25 years: 92.9-342.0 ng/mL

26-30 years: 78.4-270.0 ng/mL

31-35 years: 73.1-243.0 ng/mL

36-40 years: 69.0-227.0 ng/mL

41-45 years: 61.5-204.4 ng/mL

46-50 years: 56.8-194.5 ng/mL

51-55 years: 53.0-189.6 ng/mL

56-60 years: 45.6-172.4 ng/mL

61-65 years: 42.2-169.0 ng/mL

66-70 years: 38.3-162.5 ng/mL

71-75 years: 36.6-164.7 ng/mL

76-80 years: 34.7-164.8 ng/mL

81-85 years: 34.4-172.4 ng/mL

86-90 years: 33.6-177.8 ng/mL

 

Tanner stage reference intervals:

Males:

I : 81.3-255.3 ng/mL

II: 106.2-432.3 ng/mL

III: 244.9-511.4 ng/mL

IV: 222.6-577.7 ng/mL

V: 227.4-517.8 ng/mL

Females:

I: 85.9-323.0 ng/mL

II: 117.5-451.3 ng/mL

III: 258.3-528.5 ng/mL

IV: 224.2-585.8 ng/mL

V: 188.2-511.6 ng/mL

Tanner Stage reference source: Bindlingmaier M, Friedrich N, Emeny RT,et al. Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712-1721

 

Note: Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±2) years and for girls at a median age of 10.5 (±2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.

 

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3

1-7 days: ≤0.7 mcg/mL

8-14 days: 0.5-1.4 mcg/mL

15 days-11 months: Unavailable

1 year: 0.7-3.6 mcg/mL

2 years: 0.8-3.9 mcg/mL

3 years: 0.9-4.3 mcg/mL

4 years: 1.0-4.7 mcg/mL

5 years: 1.1-5.2 mcg/mL

6 years: 1.3-5.6 mcg/mL

7 years: 1.4-6.1 mcg/mL

8 years: 1.6-6.5 mcg/mL

9 years: 1.8-7.1 mcg/mL

10 years: 2.1-7.7 mcg/mL

11 years: 2.4-8.4 mcg/mL

12 years: 2.7-8.9 mcg/mL

13 years: 3.1-9.5 mcg/mL

14 years: 3.3-10 mcg/mL

15 years: 3.5-10 mcg/mL

16 years: 3.4-9.5 mcg/mL

17 years: 3.2-8.7 mcg/mL

18 years: 3.1-7.9 mcg/mL

19 years: 2.9-7.3 mcg/mL

20 years: 2.9-7.2 mcg/mL

21-25 years: 3.4-7.8 mcg/mL

26-30 years: 3.5-7.6 mcg/mL

31-35 years: 3.5-7.0 mcg/mL

36-40 years: 3.4-6.7 mcg/mL

41-45 years: 3.3-6.6 mcg/mL

46-50 years: 3.3-6.7 mcg/mL

51-55 years: 3.4-6.8 mcg/mL

56-60 years: 3.4-6.9 mcg/mL

61-65 years: 3.2-6.6 mcg/mL

66-70 years: 3.0-6.2 mcg/mL

71-75 years: 2.8-5.7 mcg/mL

76-80 years: 2.5-5.1 mcg/mL

81-85 years: 2.2-4.5 mcg/mL

 

Tanner Stages:

Males

Stage I: 1.4-5.2 mcg/mL

Stage II: 2.3-6.3 mcg/mL

Stage III: 3.1-8.9 mcg/mL

Stage IV: 3.7-8.7 mcg/mL

Stage V: 2.6-8.6 mcg/mL

 

Females

Stage I: 1.2-6.4 mcg/mL

Stage II: 2.8-6.9 mcg/mL

Stage III: 3.9-9.4 mcg/mL

Stage IV: 3.3-8.1 mcg/mL

Stage V: 2.7-9.1 mcg/mL

 

Note: Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±2) years and for girls at a median age of 10.5 (±2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. By contrast, for boys there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.

Day(s) Performed

Monday through Friday

Report Available

1 to 3 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

83520

84305

LOINC Code Information

Test ID Test Order Name Order LOINC Value
IGFPN IGF-1, IGFBP-3 Growth Panel In Process

 

Result ID Test Result Name Result LOINC Value
IGFB3 IGFBP-3, S 2483-6
IGF1C Insulin-Like Growth Factor 1, S 2484-4
IGF1Z Z-score 73561-3
IGFZ1 Z-score 73561-3